Chapter 2.8. Novel Therapies in Asthma: Long-Acting β2-Agonists Inhaled Corticosteroids

  1. Peter G. Gibson1,
  2. Michael Abramson2,
  3. Richard Wood-Baker3,
  4. Jimmy Volmink4,
  5. Michael Hensley5 and
  6. Ulrich Costabel6
  1. Nicola A Marks and
  2. Philip W Ind

Published Online: 25 OCT 2007

DOI: 10.1002/9780470987377.ch17

Evidence-based Respiratory Medicine

Evidence-based Respiratory Medicine

How to Cite

Marks, N. A. and Ind, P. W. (2005) Novel Therapies in Asthma: Long-Acting β2-Agonists Inhaled Corticosteroids, in Evidence-based Respiratory Medicine (eds P. G. Gibson, M. Abramson, R. Wood-Baker, J. Volmink, M. Hensley and U. Costabel), Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470987377.ch17

Editor Information

  1. 1

    John Hunter Hospital, Newcastle, New South Wales, Australia

  2. 2

    Monash University, Central & Eastern Clinical School, The Alfred, Melbourne, Victoria, Australia

  3. 3

    University of Tasmania, Hobart, Tasmania, Australia

  4. 4

    University of Cape Town, Cape Town, South Africa

  5. 5

    University of Newcastle, Newcastle, New South Wales, Australia

  6. 6

    Ruhrlandklinik, Essen, Germany

Publication History

  1. Published Online: 25 OCT 2007
  2. Published Print: 22 NOV 2005

ISBN Information

Print ISBN: 9780727916051

Online ISBN: 9780470987377



  • novel therapies in asthma;
  • inhaled corticosteroids;
  • combination inhalers;
  • leukotriene antagonists;
  • anti-immunoglobulin E


This chapter contains sections titled:

  • Introduction


  • Comparison of combination preparations with individual component drugs and placebo

  • Comparison of individual combination preparations with drugs delivered concomitantly by separate inhalers

  • Study of individual combination inhalers with other comparator drugs

  • Studies of different strategies of use of combination inhalers

  • Pharmacoeconomic studies of combination inhalers with comparators

  • Anti-immunoglobulin E for treatment of asthma in adults

  • Monoclonal anti-interleukin-5 antibody